

Allotment of acquisition cost decided by the Swedish Tax Agency

In connection with Vitrolife's distribution of the shares in Xvivo Perfusion AB, the Swedish Tax Agency has decided that 77% of the acquisition cost should be allotted to Vitrolife AB and 23% to Xvivo Perfusion AB.

Further information can be found on the Swedish Tax Agency's website and at www.vitrolife.com/en/Corporate/

December 20, 2012
Gothenburg

VITROLIFE AB (publ)
Thomas Axelsson
CEO

Queries should be addressed to:

Thomas Axelsson, CEO, phone +46 31 721 80 01
Mikael Engblom, CFO, phone +46 31 721 80 14

Vitrolife is a global biotechnology/medical device Group. Vitrolife's Fertility product area develops, produces and markets products for the treatment of human infertility. There is also business to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has ca 220 employees and its products are sold in ca 90 markets. The company is headquartered in Gothenburg, Sweden, and there are offices in USA, Australia, France, Italy, United Kingdom, China, Japan and Hungary. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.
Tel: 46 31 721 80 00. Fax: 46 31 721 80 90. E-mail: info@vitrolife.com. Website: www.vitrolife.com

Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on December 20, 2012 at 3:00 p.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.